We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The number of patent lawsuits filed over generic drug challenges has spiked this year, a development that coincides with the widely anticipated “patent cliff” of many brand drugs losing protection. Read More
AstraZeneca has filed a patent infringement lawsuit against Actavis subsidiary Watson over a proposed generic version of AZ’s diabetes drug Kombiglyze XR. Read More
A federal judge has dismissed claims brought by a group of pharmacies that Pfizer and Ranbaxy forged an illegal deal to delay generic competition to Pfizer’s cholesterol drug Lipitor, marking another victory for the manufacturers in the class action filing. Read More
HHS decided not to issue an all-encompassing regulation on the 340B drug pricing program as intended, but will keep in place its earlier interpretive rule that requires manufacturers to provide certain orphan drugs at discounts of up to 50 percent. Read More
Pharmaceutical companies today spend an average of $2.6 billion to get their products to market, according to a new report that finds R&D costs have increased 145 percent over the past decade. Read More
British generic drugmakers want branded generics to be exempt from any further price cuts on brand pharmaceuticals, arguing their products already deliver greater savings than what can be achieved from government intervention. Read More
Specialty and generic drug maker Actavis has agreed to buy botox manufacturer Allergan for $66 billion in a move analysts say could help transform Actavis into a major pharma giant. Read More
The FDA chided drugmaker Sciecure Pharma for distributing a sales aid that touted overblown superiority claims and disregarded risk information surrounding its insomnia treatment Doral.
Read More
The drug pricing authority of India is calling on industry, public health experts and others to help update the country’s list of life-saving and essential drugs, a move that one observer says is needed to understand which drugs are on the market and under price controls. Read More
The FDA wants to know how a spouse may influence a partner’s perception of a direct-to-consumer drug advertisement, the second study examining a specific DTC ad scenario that the agency has announced this week. Read More